{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:59:42Z","timestamp":1791053982134,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jaad.2020.04.009","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T11:01:17Z","timestamp":1586602877000},"page":"554-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Emerging medical treatments for hidradenitis suppurativa"],"prefix":"10.1016","volume":"83","author":[{"given":"Alexis B.","family":"Lyons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Shabeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor L.","family":"Braunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjelica","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archdermatol.2009.49","article-title":"Long-term successful adalimumab therapy in severe hidradenitis suppurativa","volume":"145","author":"Blanco","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib4","series-title":"Dermatologic Surgery","first-page":"729","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach","author":"Hurley","year":"1989"},{"issue":"20","key":"10.1016\/j.jaad.2020.04.009_bib5","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib6","first-page":"1","article-title":"Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients","volume":"19","author":"Scheinfeld","year":"2013","journal-title":"Dermatol Online J"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.smim.2013.09.005","article-title":"Functions of the skin microbiota in health and disease","volume":"25","author":"Sanford","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaad.2020.04.009_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.micpath.2017.02.024","article-title":"Gut microbiome-based medical methodologies for early-stage disease prevention","volume":"105","author":"Wang","year":"2017","journal-title":"Microb Pathog"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.det.2015.08.010","article-title":"The microbiology of hidradenitis suppurativa","volume":"34","author":"Ring","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2020.04.009_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.15007","article-title":"Bacterial biofilm in chronic lesions of hidradenitis suppurativa","volume":"176","author":"Ring","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1524-475X.2007.00283.x","article-title":"Why chronic wounds will not heal: a novel hypothesis","volume":"16","author":"Bjarnsholt","year":"2008","journal-title":"Wound Repair Regen"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1574-695X.2012.00946.x","article-title":"Considering hidradenitis suppurativa as a bacterial biofilm disease","volume":"65","author":"Kathju","year":"2012","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"10","key":"10.1016\/j.jaad.2020.04.009_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1600-0625.2012.01552.x","article-title":"Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments","volume":"21","author":"van der Zee","year":"2012","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join-Lambert","year":"2016","journal-title":"J Ntimicrob Chemother"},{"key":"10.1016\/j.jaad.2020.04.009_bib16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem\u2014a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib17","article-title":"Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system","volume":"22","author":"Scheinfeld","year":"2016","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2020.04.009_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.anaerobe.2015.05.003","article-title":"Occurrence and new mutations involved in rifampicin-resistant Propionibacterium acnes strains isolated from biofilm or device-related infections","volume":"34","author":"Furustrand Tafin","year":"2015","journal-title":"Anaerobe"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jdv.15183","article-title":"Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from hidradenitis suppurativa lesions","volume":"33","author":"Ardon","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2020.04.009_bib20","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1039\/c6pp00082g","article-title":"Photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in hidradenitis suppurativa: a retrospective follow-up study in 7 patients and a review of the literature","volume":"15","author":"Agut-Busquet","year":"2016","journal-title":"Photochem Photobiol Sci"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/09546630902882063","article-title":"Pulsed dye laser-mediated photodynamic therapy for acne inversa is not successful: a pilot study on four cases","volume":"20","author":"Passeron","year":"2009","journal-title":"J Dermatol Treat"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2133.2005.06475.x","article-title":"Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa","volume":"152","author":"Strauss","year":"2005","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.04.009_bib23","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1111\/j.1365-2230.2008.03094.x","article-title":"Treatment of recalcitrant hidradenitis suppurativa with photodynamic therapy: report of five cases","volume":"34","author":"Sotiriou","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","article-title":"The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis","volume":"9","author":"Schon","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.009_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjd.17854","article-title":"A new Th-17 cytokine in hidradenitis suppurativa: antimicrobial and pro-inflammatory role of IL-26","volume":"181","author":"Scala","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib27","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjd.14703","article-title":"The many faces of interleukin-17 in inflammatory skin diseases","volume":"175","author":"Speeckaert","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib28","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jaad.2020.04.009_bib29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib30","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib31","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.15769","article-title":"Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib33","unstructured":"Wiendl H, Dahlke F, Bennett D, Rosenkranz G, Wold C, Bar-Or A. IL-17 neutralization by subcutaneous CJM112, a fully human anti IL-17A monoclonal antibody for the treatment of relapsing-remitting multiple\u00a0sclerosis: study design of a phase 2 trial. Paper\u00a0presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. October 7\u201310, 2015; Barcelona, Spain."},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib36","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Ann Rev Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib39","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2020.04.009_bib40","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2020.04.009_bib42","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejcb.2010.04.008","article-title":"Interleukin-1, inflammasomes and the skin","volume":"89","author":"Feldmeyer","year":"2010","journal-title":"Eur J Cell Biol"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.009_bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/ejd.2013.2018","article-title":"Pyoderma gangrenosum and concomitant hidradenitis suppurativa\u2014rapid response to canakinumab (anti-IL-1beta)","volume":"23","author":"Jaeger","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.04.009_bib45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"issue":"9317","key":"10.1016\/j.jaad.2020.04.009_bib46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib48","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.009_bib49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","volume":"81","author":"Oskardmay","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaad.2019.09.012","article-title":"Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review","volume":"82","author":"Wang","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.04.009_bib51","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.dld.2016.09.010","article-title":"Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab","volume":"48","author":"Tursi","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.04.009_bib53","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2020.04.009_bib54","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.2174\/1874467210666170113104503","article-title":"Tofacitinib, an oral Janus kinase inhibitor: perspectives in dermatology","volume":"24","author":"Kostovic","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jaad.2020.04.009_bib55","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: a systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib56","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib57","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","article-title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","volume":"75","author":"Feldman","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib58","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients","volume":"6","author":"Savage","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.04.009_bib63","unstructured":"Alavi A. What's new in the treatment pipeline for hidradenitis suppurativa? Paper presented at: Symposium on Hidradenitis Suppurativa Advances 2018; October 12\u201314, 2018, Toronto, Ontario."},{"key":"10.1016\/j.jaad.2020.04.009_bib64","unstructured":"Zenker OT. Dose-finding study of IFX-1 in moderate to severe hidradenitis suppurativa using the MCP-Mod procedure. Paper presented at: Symposium of Hidradenitis Suppurativa Advances 2018; October 12\u201314, 2018, Toronto, Ontario."},{"key":"10.1016\/j.jaad.2020.04.009_bib65","unstructured":"Zenker OT. Long-term efficacy of IFX-1 in severe hidradenitis suppurativa: report of a case. Paper presented at: Symposium on Hidradenitis Suppurativa Advances 2018; October 12\u201314, 2018, Toronto, Ontario."},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2230.2002.11125.x","article-title":"Methotrexate is of limited value in the treatment of hidradenitis suppurativa","volume":"27","author":"Jemec","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib67","first-page":"185","article-title":"SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate","volume":"69","author":"De Souza","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib68","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2230.2005.01983.x","article-title":"Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin","volume":"31","author":"Rose","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.009_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjd.12104","article-title":"Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review","volume":"168","author":"Blok","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib70","first-page":"289p","article-title":"Cyclosporin-responsive hidradenitis suppurativa","volume":"88","author":"Buckley","year":"1995","journal-title":"J R Soc Med"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.009_bib71","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archderm.1990.01670270071012","article-title":"Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis","volume":"126","author":"Gupta","year":"1990","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.009_bib72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","article-title":"Cyclosporine treatment of severe Hidradenitis suppurativa\u2014a case series","volume":"27","author":"Anderson","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic\u00a0corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.009_bib74","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","article-title":"Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa","volume":"75","author":"Wong","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib75","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2016.06.049","article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series","volume":"75","author":"Riis","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.009_bib76","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.15233","article-title":"The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide","volume":"177","author":"Jennings","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.009_bib77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci (Lond)"},{"issue":"9","key":"10.1016\/j.jaad.2020.04.009_bib78","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","article-title":"Metformin for the treatment of hidradenitis suppurativa: a little help along the way","volume":"27","author":"Verdolini","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib79","first-page":"239","article-title":"The role of androgens and estrogens in hidradenitis suppurativa\u2014a systematic review","volume":"24","author":"Riis","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"issue":"7","key":"10.1016\/j.jaad.2020.04.009_bib80","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bpobgyn.2014.07.012","article-title":"Hidradenitis suppurativa","volume":"28","author":"Margesson","year":"2014","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMct0707092","article-title":"Metformin for the treatment of the polycystic ovary syndrome","volume":"358","author":"Nestler","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.009_bib82","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.1988.tb03227.x","article-title":"The symptomatology of hidradenitis suppurativa in women","volume":"119","author":"Jemec","year":"1988","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib83","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2133.1991.tb14162.x","article-title":"Androgen metabolism by isolated human axillary apocrine glands in hidradenitis suppurativa","volume":"125","author":"Barth","year":"1991","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.009_bib84","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000100883","article-title":"Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study","volume":"214","author":"Brocard","year":"2007","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.009_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.det.2015.08.005","article-title":"Endocrinologic aspects of hidradenitis suppurativa","volume":"34","author":"Karagiannidis","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2020.04.009_bib86","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.009_bib87","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030548X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030548X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:57Z","timestamp":1759273017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222030548X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S019096222030548X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.009","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging medical treatments for hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}